Vertex Pharmaceuticals (WBO:VRTX) Quality Rank


WBO:VRTX Vertex Pharmaceuticals Inc WBO:VRTX
85 GF Score
Price €424.75
GF Value €437.40
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Vertex Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Vertex Pharmaceuticals Quality Rank Related Terms

WBO:VRTX
85GF Score
Vertex Pharmaceuticals Inc WBO:VRTX
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vertex Pharmaceuticals (WBO:VRTX) Overvalued in 2026?

Based on GuruFocus' analysis, Vertex Pharmaceuticals stock appears to be undervalued. The current stock price of €424.75 is trading 2.9% below its estimated GF Value™ of €437.40. GuruFocus considers Vertex Pharmaceuticals to be Fairly Valued.

Key valuation signals for WBO:VRTX:

  • Quality Rank:
  • GF Value™: €437.40 vs. price of €424.75 (2.9% below fair value)
  • GF Score™: 85/100 with 5 warning signs

No single metric tells the full story. See the WBO:VRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vertex Pharmaceuticals Business Description

Address 50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
85GF Score

Get the complete analysis for WBO:VRTX

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€424.75
Price
€437.40
GF Value